331 related articles for article (PubMed ID: 22773548)
1. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies.
Chen HP; Shieh JJ; Chang CC; Chen TT; Lin JT; Wu MS; Lin JH; Wu CY
Gut; 2013 Apr; 62(4):606-15. PubMed ID: 22773548
[TBL] [Abstract][Full Text] [Related]
2. Low concentration of metformin induces a p53-dependent senescence in hepatoma cells via activation of the AMPK pathway.
Yi G; He Z; Zhou X; Xian L; Yuan T; Jia X; Hong J; He L; Liu J
Int J Oncol; 2013 Nov; 43(5):1503-10. PubMed ID: 23982736
[TBL] [Abstract][Full Text] [Related]
3. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease.
Donadon V; Balbi M; Mas MD; Casarin P; Zanette G
Liver Int; 2010 May; 30(5):750-8. PubMed ID: 20331505
[TBL] [Abstract][Full Text] [Related]
4. Metformin suppresses hepatocellular carcinoma cell growth through induction of cell cycle G1/G0 phase arrest and p21CIP and p27KIP expression and downregulation of cyclin D1 in vitro and in vivo.
Cai X; Hu X; Cai B; Wang Q; Li Y; Tan X; Hu H; Chen X; Huang J; Cheng J; Jing X
Oncol Rep; 2013 Nov; 30(5):2449-57. PubMed ID: 24008375
[TBL] [Abstract][Full Text] [Related]
5. Authors' response: Metformin and risk of hepatocellular carcinoma--a study focused on anti-diabetic agents.
Wu CY; Chen HP
Gut; 2013 Jun; 62(6):952. PubMed ID: 23355550
[No Abstract] [Full Text] [Related]
6. Metformin and risk of hepatocellular carcinoma: are statins the missing link?
Singh S; Singh PP
Gut; 2013 Jun; 62(6):951-2. PubMed ID: 23263525
[No Abstract] [Full Text] [Related]
7. Effect of the anti-diabetic drug metformin in hepatocellular carcinoma in vitro and in vivo.
Miyoshi H; Kato K; Iwama H; Maeda E; Sakamoto T; Fujita K; Toyota Y; Tani J; Nomura T; Mimura S; Kobayashi M; Morishita A; Kobara H; Mori H; Yoneyama H; Deguchi A; Himoto T; Kurokohchi K; Okano K; Suzuki Y; Murao K; Masaki T
Int J Oncol; 2014 Jul; 45(1):322-32. PubMed ID: 24806290
[TBL] [Abstract][Full Text] [Related]
8. Silibinin efficacy against human hepatocellular carcinoma.
Varghese L; Agarwal C; Tyagi A; Singh RP; Agarwal R
Clin Cancer Res; 2005 Dec; 11(23):8441-8. PubMed ID: 16322307
[TBL] [Abstract][Full Text] [Related]
9. Metformin does not improve survival in patients with hepatocellular carcinoma.
Bhat M; Chaiteerakij R; Harmsen WS; Schleck CD; Yang JD; Giama NH; Therneau TM; Gores GJ; Roberts LR
World J Gastroenterol; 2014 Nov; 20(42):15750-5. PubMed ID: 25400459
[TBL] [Abstract][Full Text] [Related]
10. Swainsonine inhibits growth and potentiates the cytotoxic effect of paclitaxel in hepatocellular carcinoma in vitro and in vivo.
You N; Liu W; Wang T; Ji R; Wang X; Gong Z; Dou K; Tao K
Oncol Rep; 2012 Dec; 28(6):2091-100. PubMed ID: 22993037
[TBL] [Abstract][Full Text] [Related]
11. Adiponectin and metformin additively attenuate IL1β-induced malignant potential of colon cancer.
Moon HS; Mantzoros CS
Endocr Relat Cancer; 2013 Dec; 20(6):849-59. PubMed ID: 24157941
[TBL] [Abstract][Full Text] [Related]
12. Anti-angiogenic effect of metformin in human liver carcinogenesis related to metabolic syndrome.
Cauchy F; Mebarki M; Albuquerque M; Laouirem S; Rautou PE; Soubrane O; Raymond E; Bedossa P; Paradis V
Gut; 2015 Sep; 64(9):1498-500. PubMed ID: 26123027
[No Abstract] [Full Text] [Related]
13. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells.
Fornari F; Gramantieri L; Giovannini C; Veronese A; Ferracin M; Sabbioni S; Calin GA; Grazi GL; Croce CM; Tavolari S; Chieco P; Negrini M; Bolondi L
Cancer Res; 2009 Jul; 69(14):5761-7. PubMed ID: 19584283
[TBL] [Abstract][Full Text] [Related]
14. Metformin displays anti-myeloma activity and synergistic effect with dexamethasone in in vitro and in vivo xenograft models.
Zi FM; He JS; Li Y; Wu C; Yang L; Yang Y; Wang LJ; He DH; Zhao Y; Wu WJ; Zheng GF; Han XY; Huang H; Yi Q; Cai Z
Cancer Lett; 2015 Jan; 356(2 Pt B):443-53. PubMed ID: 25305450
[TBL] [Abstract][Full Text] [Related]
15. Involvement of p21(WAF1/Cip1), p27(Kip1), and p18(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines.
Koga H; Sakisaka S; Harada M; Takagi T; Hanada S; Taniguchi E; Kawaguchi T; Sasatomi K; Kimura R; Hashimoto O; Ueno T; Yano H; Kojiro M; Sata M
Hepatology; 2001 May; 33(5):1087-97. PubMed ID: 11343236
[TBL] [Abstract][Full Text] [Related]
16. The effect of doxorubicin on MEK-ERK signaling predicts its efficacy in HCC.
Choi J; Yip-Schneider M; Albertin F; Wiesenauer C; Wang Y; Schmidt CM
J Surg Res; 2008 Dec; 150(2):219-26. PubMed ID: 18468633
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels.
Baiz D; Pozzato G; Dapas B; Farra R; Scaggiante B; Grassi M; Uxa L; Giansante C; Zennaro C; Guarnieri G; Grassi G
Biochimie; 2009 Mar; 91(3):373-82. PubMed ID: 19041685
[TBL] [Abstract][Full Text] [Related]
18. Ethyl acetate extraction from a Chinese herbal formula, Jiedu Xiaozheng Yin, inhibits the proliferation of hepatocellular carcinoma cells via induction of G0/G1 phase arrest in vivo and in vitro.
Cao Z; Lin W; Huang Z; Chen X; Zhao J; Zheng L; Ye H; Liu Z; Liao L; Du J
Int J Oncol; 2013 Jan; 42(1):202-10. PubMed ID: 23165653
[TBL] [Abstract][Full Text] [Related]
19. Antidiabetic drug metformin inhibits esophageal adenocarcinoma cell proliferation in vitro and in vivo.
Fujihara S; Kato K; Morishita A; Iwama H; Nishioka T; Chiyo T; Nishiyama N; Miyoshi H; Kobayashi M; Kobara H; Mori H; Okano K; Suzuki Y; Masaki T
Int J Oncol; 2015 May; 46(5):2172-80. PubMed ID: 25709052
[TBL] [Abstract][Full Text] [Related]
20. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study.
Lai SW; Chen PC; Liao KF; Muo CH; Lin CC; Sung FC
Am J Gastroenterol; 2012 Jan; 107(1):46-52. PubMed ID: 22085817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
